Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Stateside's Canadian Microcap Board -- Ignore unavailable to you. Want to Upgrade?

To: statesidereport who wrote (1597)	4/14/2016 5:49:26 PM
From: PoorOpinion	Read Replies (1) \| Respond to of 1728

A little more on the bct executive team. I had hoped that Joseph Wagner had parted with bct for positive reasons, like he'd been headhunted by a bigger biotech. A few days after his departure his linkedin still had him as ceo of bct, now he's " independant consultant" and "executive for hire", so it looks like he didnt leave bct for another position. linkedin.com

To: statesidereport who wrote (1597)	4/15/2016 7:31:04 AM
From: Dave@SI	Read Replies (1) \| Respond to of 1728

TLT NR today re paper published about the transferrin benefit to TLD-1433. You've got to admire their futuristic writing style: "Theralase is focused on successfully completing a Phase Ib..." Which might be edited by the less sanguine as: "Theralase is focused on successfully starting* a Phase Ib ...*" As I remember it the transferrin-enhancement does not get used in the pending trial? A: Yes/No/Your guess is as good as mine - Delete as appropriate. BTW, BCT are at AACR on Monday, anyone feel like buying in advance of the rush? Thought not. I am still long here (both), just a bit bored and cynical.